What were the most significant outcomes of the Annual Meeting of Shareholders?

The most significant outcomes were the re-election of all directors to the Board, the ratification of Ernst & Young LLP as auditors, and the approval of executive compensation. Most shareholder-initiated proposals, concerning governance and reporting, were not approved.

How did shareholders vote on the company's executive compensation?

Shareholders approved the compensation of Abbott's named executive officers in an advisory vote, with 91.27% of the votes cast voting in favor of the proposal.

Were there any shareholder proposals that were approved?

No, all shareholder proposals presented at the meeting were rejected by the majority of the votes cast. The closest a proposal came to approval was the one requesting a lower ownership threshold for calling special meetings, which received 47.15% of the votes cast in favor.

What does the high number of broker non-votes mean for the results?

Broker non-votes represent shares held by brokers that did not receive voting instructions from the beneficial owner. While a significant number of broker non-votes were recorded for the director elections and executive compensation vote, the proposals that were close (like the special meetings threshold) or rejected still failed to gain majority support even when considering these votes. For the proposals that passed by a large margin, the broker non-votes had minimal impact on the outcome.

ABT 8-K: Shareholder Matters

Summary

This 8-K filing from Abbott Laboratories details the outcomes of its Annual Meeting of Shareholders held on April 29, 2022. Key investor-focused information includes the overwhelming re-election of the entire Board of Directors and the ratification of Ernst & Young LLP as the company's auditor. Shareholders also approved the compensation of named executive officers in an advisory vote. The filing also outlines several shareholder proposals that were rejected by the majority of votes cast, including proposals related to special meeting thresholds, independent board chair, Rule 10b5-1 plans, lobbying expenditures, and antimicrobial resistance reporting. From an investor's perspective, the broad support for the board and auditor indicates a level of confidence in current management and governance. The rejection of most shareholder proposals suggests that the board's current strategies and policies are favored by the majority of shareholders, or at least that the proposals did not garner sufficient support to pass. The advisory vote on executive compensation passing with over 91% approval is a positive signal regarding shareholder alignment on pay practices.

Key Highlights

1Abbott Laboratories shareholders overwhelmingly re-elected all members of the Board of Directors.
2The appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year was ratified by shareholders.
3An advisory vote on the compensation of Abbott's named executive officers was approved, with 91.27% of the votes cast in favor.
4A shareholder proposal to lower the ownership threshold for calling special meetings was rejected, with only 47.15% voting in favor.
5Shareholder proposals regarding an independent board chairman, restrictions on Rule 10b5-1 plans, and lobbying disclosures and expenditures were all rejected.
6A shareholder proposal requesting a report on the public health costs and financial market impacts of Abbott's antimicrobial resistance standards was also rejected with a low percentage of 'For' votes.

ABBOTT LABORATORIES 8-K Report, Shareholder Vote Results (May 2, 2022)

Summary

Key Highlights

Frequently Asked Questions